A Phase II, Open-Label, Single- Center Study to Assess the Activity of Oshadi D and Oshadi R in Combination With Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) Patients
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2018
At a glance
- Drugs Oshadi D (Primary) ; Oshadi R (Primary) ; Cytarabine; Mitoxantrone
- Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Oshadi Drug Administration
- 16 Apr 2018 Status changed from not yet recruiting to suspended.
- 28 Mar 2016 Planned End Date changed from 1 Jun 2017 to 1 Dec 2018 as per ClinicalTrials.gov record.
- 28 Mar 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2018 as per ClinicalTrials.gov record.